PTC Therapeutics (PTCT) Officer Plans Sale of 25,562 Shares ($1.69M)

PTC Therapeutics (PTCT) submitted a Form 144 notice for a proposed sale of 25,562 common shares with an aggregate market value of $1,685,979.27, planned for 10/03/2025 on NASDAQ.

Rhea-AI Filing Summary

PTC Therapeutics (PTCT) submitted a Form 144 notice for a proposed sale of 25,562 common shares with an aggregate market value of $1,685,979.27, planned for 10/03/2025 on NASDAQ. The shares correspond to option exercises granted on 12/14/2018 (8,650 shares), 01/22/2019 (6,912 shares) and 01/05/2023 (10,000 shares); payment for these shares is shown as cash on 10/03/2025. The filing lists a recent sale on 09/11/2025 of 15,705 common shares that generated $934,447.50 in gross proceeds by a seller identified as Emma Reeve. The notice includes the required representation that the signer does not possess undisclosed material adverse information about the issuer.

Positive

• Proposed sale quantity is precisely disclosed: 25,562 shares for $1,685,979.27
• Source of shares is documented with grant dates: 12/14/2018, 01/22/2019, 01/05/2023
• Previous recent sale is disclosed with amount and proceeds: 15,705 shares for $934,447.50

Negative

• Filer CIK and contact fields are not provided in the visible content
• The filing does not identify whether the seller signing the Form 144 is the same person named in the prior sale (Emma Reeve)

Insights

Insider Transactions Analyst

Large planned sale of vested option shares worth $1.69M on 10/03/2025.

The filing shows an insider-linked sale notice for 25,562 shares derived from vested option grants dated between 2018 and 2023, with cash payment recorded on the sale date.

This is a routine Rule 144 notice documenting a proposed public sale on NASDAQ; the earlier sale of 15,705 shares on 09/11/2025 produced $934,447.50 in gross proceeds, indicating prior dispositions in the same period.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filed for PTCT report?

It reports a proposed sale of 25,562 common shares of PTC Therapeutics with an aggregate market value of $1,685,979.27, planned for 10/03/2025 on NASDAQ.

What is the origin of the 25,562 shares in the PTCT Form 144?

The shares come from option grants dated 12/14/2018 (8,650 shares), 01/22/2019 (6,912 shares) and 01/05/2023 (10,000 shares), with payment shown as cash on 10/03/2025.

Did the filer recently sell other PTCT shares?

Yes. The filing discloses a sale on 09/11/2025 of 15,705 common shares that produced $934,447.50 in gross proceeds by a seller identified as Emma Reeve.

On which exchange will the PTCT shares be sold?

The proposed sale is listed to occur on NASDAQ.

Does the Form 144 assert the seller has material nonpublic information?

By signing, the person represents they do not know any undisclosed material adverse information about the issuer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/03/2025 - 04:38 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001680329
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	PTC THERAPEUTICS, INC.
SEC File Number	001-35969
Address of Issuer	500 WARREN CORPORATE CENTER DRIVE WARREN NEW JERSEY 07059
Phone	9082227000
Name of Person for Whose Account the Securities are To Be Sold	Reeve Emma
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	25562	1685979.27	79438094	10/03/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/03/2025	Option Granted - 12/14/2018	Issuer			8650	10/03/2025	Cash
Common	10/03/2025	Option Granted - 01/22/2019	Issuer			6912	10/03/2025	Cash
Common	10/03/2025	Option Granted - 01/05/2023	Issuer			10000	10/03/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Emma Reeve 500 Warren Corporate Center Drive Warren NJ 07059	Common	09/11/2025	15705	934447.50

144: Remarks and Signature

Remarks
Date of Notice	10/03/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/04/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jennifer Ruchti, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Emma Reeve
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)